WO2007045907A3 - Ramipril formulation with increased stability - Google Patents

Ramipril formulation with increased stability Download PDF

Info

Publication number
WO2007045907A3
WO2007045907A3 PCT/GB2006/003927 GB2006003927W WO2007045907A3 WO 2007045907 A3 WO2007045907 A3 WO 2007045907A3 GB 2006003927 W GB2006003927 W GB 2006003927W WO 2007045907 A3 WO2007045907 A3 WO 2007045907A3
Authority
WO
WIPO (PCT)
Prior art keywords
ramipril
increased stability
formulation
ramipril formulation
ramiprilat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2006/003927
Other languages
French (fr)
Other versions
WO2007045907A2 (en
Inventor
Paul Jonathan Harrison
Anna Marie Elizabeth Power
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Selamine Ltd
Original Assignee
Selamine Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0521529A external-priority patent/GB0521529D0/en
Priority claimed from GB0522047A external-priority patent/GB2431579A/en
Priority claimed from US11/508,916 external-priority patent/US20070098782A1/en
Application filed by Selamine Ltd filed Critical Selamine Ltd
Priority to CA002626613A priority Critical patent/CA2626613A1/en
Priority to EP06794863A priority patent/EP1937220A2/en
Priority to AU2006303068A priority patent/AU2006303068A1/en
Publication of WO2007045907A2 publication Critical patent/WO2007045907A2/en
Publication of WO2007045907A3 publication Critical patent/WO2007045907A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A pharmaceutical formulation contains ramipril principally in the form of a ramipril salt and is buffered at basic pH. Ramipril in the formulation degrades preferentially to the diacid, ramiprilat, rather than the diketopiperazine.
PCT/GB2006/003927 2005-10-21 2006-10-23 Ramipril formulation with increased stability Ceased WO2007045907A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002626613A CA2626613A1 (en) 2005-10-21 2006-10-23 Ramipril formulation with increased stability
EP06794863A EP1937220A2 (en) 2005-10-21 2006-10-23 Ramipril formulation with increased stability
AU2006303068A AU2006303068A1 (en) 2005-10-21 2006-10-23 Ramipril formulation with increased stability

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB0521529A GB0521529D0 (en) 2005-10-21 2005-10-21 Ramipril formulation
GB0521529.8 2005-10-21
GB0522047.0 2005-10-28
GB0522047A GB2431579A (en) 2005-10-28 2005-10-28 Ramipril formulations
US11/273,575 US20070259941A1 (en) 2005-10-28 2005-11-15 Ramipril formulation
US11/273,575 2005-11-15
US11/508,916 2006-08-24
US11/508,916 US20070098782A1 (en) 2005-10-28 2006-08-24 Ramipril Formulation

Publications (2)

Publication Number Publication Date
WO2007045907A2 WO2007045907A2 (en) 2007-04-26
WO2007045907A3 true WO2007045907A3 (en) 2007-08-30

Family

ID=37909496

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/003927 Ceased WO2007045907A2 (en) 2005-10-21 2006-10-23 Ramipril formulation with increased stability

Country Status (3)

Country Link
EP (1) EP1937220A2 (en)
AU (1) AU2006303068A1 (en)
WO (1) WO2007045907A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215526A1 (en) * 2002-03-08 2003-11-20 Scott Stofik Stable formulations of angiotensin converting enzyme (ACE) inhibitors
WO2005007130A1 (en) * 2003-07-11 2005-01-27 Sandoz Ag Stable pharmaceutical compositions containing an ace inhibitor
WO2005067887A2 (en) * 2004-03-24 2005-07-28 Actavis Group Formulations of ramipril
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215526A1 (en) * 2002-03-08 2003-11-20 Scott Stofik Stable formulations of angiotensin converting enzyme (ACE) inhibitors
WO2005007130A1 (en) * 2003-07-11 2005-01-27 Sandoz Ag Stable pharmaceutical compositions containing an ace inhibitor
WO2005067887A2 (en) * 2004-03-24 2005-07-28 Actavis Group Formulations of ramipril
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200612, Derwent World Patents Index; AN 2006-112723, XP002438453 *

Also Published As

Publication number Publication date
AU2006303068A1 (en) 2007-04-26
WO2007045907A2 (en) 2007-04-26
EP1937220A2 (en) 2008-07-02

Similar Documents

Publication Publication Date Title
USD522870S1 (en) Bottle
AU2003289641A1 (en) The novel coumarin-amide derivatives and its preparation, said drug composition and its use
AU2003293649A1 (en) Novel xanthine derivatives, the production and the use thereof in the form of drugs
PL1656095T3 (en) N,n-dihalogenated amino acids and derivatives
WO2007104780A3 (en) N- carbamoylmethyl- 4- (r) -phenyl-2-pyrr0lidin0ne, method of its preparation and pharmaceutical use
IL168102A0 (en) Chk-, pdk-and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
DE502005002105D1 (en) 4-BENZIMIDAZOLE-2-YL-PYRIDAZINE-3-ON DERIVATIVES, THEIR PREPARATION AND THEIR ADMINISTRATION
SI1720872T1 (en) Aryl and heteroaryl-piperidinecarboxylate derivatives, the preparation and the use thereof in the form of faah enzyme inhibitors
PL1879936T3 (en) Aqueous emulsion of alpha-silyl terminated polymers that is stable in storage, production of said emulsion and use of the latter
EP1724278A4 (en) Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
IL182054A0 (en) Novel bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors
WO2007102913A3 (en) Phospholipid-stabilized oxidizable material
WO2005032490A3 (en) Cyclic diamines and derivatives as factor xa inhibitors
EP1946639A3 (en) DDGS as a low-cost flavor enhancer and sodium reduction enabler
WO2005067887A3 (en) Formulations of ramipril
USD515837S1 (en) Sofa
PL374879A1 (en) Indoline derivatives substituted in position 6, production and use thereof as medicaments
CA114483S (en) Bottle
USD541165S1 (en) Combined bottle and cap
AU2003254556A1 (en) Indoline derivatives substituted in position 6, production and use thereof as medicaments
WO2005105740A3 (en) Preparation of tegaserod and tegaserod maleate
RU2005104060A (en) METHOD FOR PREVENTION OF ANIMAL MYCOTOXICOSIS
WO2007045353A3 (en) Combined preparation of o-acetylsalicylic acid salts
WO2007062336A3 (en) Salt forms
WO2004111088A3 (en) Angiogenic factor and inhibitors thereof

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2006794863

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 566600

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2006303068

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2006303068

Country of ref document: AU

Date of ref document: 20061023

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006303068

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2626613

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2006794863

Country of ref document: EP